Details for Patent: 11,071,742

Which drugs does patent 11,071,742 protect, and when does it expire?

Patent 11,071,742 protects RELYVRIO and is included in one NDA.

This patent has forty-nine patent family members in twenty countries.

Summary for Patent: 11,071,742

Title:	Compositions for improving cell viability and methods of use thereof
Abstract:	This invention relates to methods and compositions for use improving cell viability, particularly neural cell viability, and more particularly to methods and compositions for use improving cell viability by reducing reactive oxygen metabolite-mediated oxidative damage in a cell, regulating redox homeostasis in a cell, or reducing mitochondrial dysfunction in a cell. The invention further relates to the administration of the bile acid tauroursodeoxycholic acid (TUDCA) in combination with phenylbutyric Acid (PBA) to improve cell viability, and treat at least one symptom associated with, prevent the time of onset of, or slow the development of a disease related to oxidative stress.
Inventor(s):	Joshua Cohen, Justin Klee
Assignee:	Amylyx Pharmaceuticals Inc
Application Number:	US16/280,861
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 11,071,742

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Amylyx	RELYVRIO	sodium phenylbutyrate; taurursodiol	FOR SUSPENSION;ORAL	216660-001	Sep 29, 2022		DISCN	Yes	No			Y

International Family Members for US Patent 11,071,742

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014242123
Australia	2019200658
Australia	2021201770
Australia	2022221410
Australia	2025201758